<DOC>
	<DOCNO>NCT00179816</DOCNO>
	<brief_summary>This study use double autologous peripheral blood stem cell rescue ( PBSC ) follow dose-intensive chemotherapy treatment high-risk pediatric solid tumor .</brief_summary>
	<brief_title>Tandem Peripheral Blood Stem Cell ( PBSC ) Rescue High Risk Solid Tumors</brief_title>
	<detailed_description>Significant advance make recent year treatment solid tumor childhood . However , much improvement survival make low stage localize disease . Of significance fact improvement come up-front remission rate without translation significantly high event-free survival ( EFS ) overall survival ( OS ) . This despite fact tumor whole largely chemotherapy responsive . Recent advance understand biology hematopoeitic stem cell driven design treatment regimens allow dose intensification without unacceptable hematologic toxicity . Protocol development focus active agent broad range hematologic non-hematologic toxicity . This study use double autologous peripheral blood stem cell rescue ( PBSC ) follow dose-intensive chemotherapy treatment high-risk pediatric solid tumor . This study utilize PBSC limit risk tumor cell contamination retain prompt hematologic recovery highly intensified treatment .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Malignant Diseases : Ewing 's sarcoma/PNET : CR1 Metastatic disease diagnosis , tumor volume &gt; 100 ml , pelvic bone primary CR2 Locally recurrent disease Soft tissue sarcoma CR1 Metastatic disease diagnosis locally advanced disease local control suboptimal ( i.e. , inability provide radiation therapy due extent disease ) . CR2 Locally recurrent disease ( VGPR2 acceptable ) Hepatoblastoma : VGPR1 Patients metastatic disease diagnosis persistently elevate alpha FP , unresectable primary way convert resectable . CR2/VGPR2 Hodgkin 's Disease : VGPR1 Progression primary therapy/Refractory disease CR2/VGPR2 Germ Cell Tumor : CR2/VGPR2 recurrent disease Wilms Tumor : CR2/VGPR2 recurrent disease IRB approve sign write informed consent patient and/or legally authorize guardian . Patients 21 year age young initial diagnosis , old patient consider individually primary pediatric disease diagnosis . Adequate central venous access ( double lumen CVL 2 single lumen PCVC ) . Adequate PBSC harvest minimum 2.0 x 108 MNC/kg available PBSC rescue . Organ Function : Platelets &gt; 50,000/ml SGOT &lt; 10 x upper limit normal Creatinine &lt; 1.5 x normal baseline Normal cardiac function accordance institutional policy Normal pulmonary function accordance institutional policy . Physiologic status : No active infection Adequate performance status measure Karnofsky ( &gt; 70 % ) Lansky scale ( &gt; 60 % ) appropriate age . Bone Marrow Status No evidence morphologic involvement tumor time transplant Off Study Criteria : Severe toxicity . Contact Study Coordinator immediately complete Adverse Reaction Form . Disease progression relapse prior PBSC # 1 PBSC rescue # 1 # 2 . Inability collect adequate number PBSC successful transplantation . Patient parent/guardian refusal remain study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>wilm 's tumor</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>solid tumor</keyword>
</DOC>